The example of IL-2 withdrawal in T cells [42], in which a FOXO3a downstream target, GILZ, protects T cells from apoptosis, would provide a model of a FOXO3a role in HOZOT.
This work is of importance as it provides an example of IL-10 regulation at the cell-to-cell and molecular level via coordination of two signals from two cell types.
More importantly, this not only serves as an example of IL-10 regulation at the cellular via coordination of two signals from two cell types, but these findings also lay the molecular and cellular groundwork for future studies to investigate how to manipulate IL-10 or IL-30 production during inflammation, cancer, or autoimmune diseases.
In addition, myoFBs themselves produce and secrete a number of cytokines (for example, IL-1α, IL-1β, IL-6, IL-10 and TNFα), which in turn help to maintain the inflammatory response to injury [ 25].
Figure 3H and I show typical examples of IL-6 staining at different stages of disease.
Examples of IL-17A+ and IL-17F+ cells in the bronchial submucosa in asthma are as shown in Figures 1A– 1A.
Examples of IL-17A+ and IL-17F+ cells in the bronchial submucosa in COPD are as shown in Figures 2A– 2A.
One of the promising examples of IL-12 in immunoprophylaxis is the development of a vaccine against leishmaniasis, an infectious disease caused by Leishmania parasites that kills 50,000 people a year worldwide.
IL-6 is just one of a handful of proinflammatory factors (for example, IL-1β, IL-21, and IL-23) that can work singly and in combination to drive human Th17 development [ 49, 50, 52, 53].
For example, expression of IL-1α, IL-6, and IL-8 was restricted to the cell lines MDA-MB-231, TMD-231, LMD-231, MDA-MB-436, TMD-436, Hs578T, and HBL-100; however, sensitive RT-PCR assay revealed IL-8 expression in several cell lines at variable levels.
For example, polymorphisms of IL-21 and its receptor were identified in patient samples associated with Type 1 diabetes (53).
